In 2010, the medical press was full of stories concerning a link between the long-acting insulin analogue, glargine, and various forms of cancer. A year later, the French authorities banned pioglitazone, on the basis that it might increase the risk of bladder cancer. Although neither of these links have been substantiated (and both agents remain part of NICE guidance in the UK), the spectre of increased cancer risk has now fallen on a novel diabetes pipeline agent, threatening to slow its launch.

Read More ››